Dimming the state’s literary light
September 27, 2019/by Jamie GassTackling equity at Boston’s exam schools
August 5, 2019/by Jim StergiosMelville readies students for rough seas ahead
July 31, 2019/by Jamie GassThe Supreme Court Is Set To Decide Whether Religious Kids Are Allowed A Good Education
July 19, 2019/by Jamie GassBoston companies can partner with public universities to create fintech skills pipeline
July 12, 2019/by Eamon McCarthy EarlsReport: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework
June 26, 2019/by Editorial StaffDenying students the opportunity to study classic works of literature leads to a culture of mediocrity
June 20, 2019/by Jamie GassMore students, employers need to benefit from voc-tech schools’ winning formula
June 19, 2019/by Tom BirminghamPutting a Price on Life: The Coming Fight Over Government Rationing of Medical Care
June 12, 2019/by Editorial StaffThe Mass. Pike is in for some massive disruption. Are we ready?
May 31, 2019/by Mary ConnaughtonTo Keep Our Republic, American Students Must Study The French Revolution
May 31, 2019/by Jamie GassUber May Not Be Perfect, But Do We Want To Give The Transportation Revolution A Flat Tire?
May 16, 2019/by Jim StergiosHow Massachusetts Showed the Way on Education Reform
May 16, 2019/by Jamie GassMass Pike rebuild shouldn’t impact Worcester commuters, but it will
May 3, 2019/by Mary ConnaughtonGuglielmo Marconi and the importance of innovation and choice in education
May 1, 2019/by Jamie GassHere’s why Sarah Palin’s ‘death panels’ are now being debated in Massachusetts
April 25, 2019/by Editorial StaffIssue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology
April 23, 2019/by Editorial StaffCommentary: Proposed Drug Price Caps Would Stall Advances in Health Care
April 23, 2019/by Editorial StaffHHS Secretary Alex Azar doesn’t want drug access to become an equation
April 18, 2019/by Editorial StaffAction on health care pricing transparency needed to stem rising costs
April 12, 2019/by Jim StergiosThe U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews
February 22, 2019/by Editorial Staff
Scroll to top
